Clinical Trial Update: A Safety and Efficacy Study of Symbicort Turbuhaler Compared With Standard Chronic Obstructive Pulmonary Disease (COPD) Treatment in Japan [Phase 3]

View source ↗

Summary

This Phase 3 study in Japan compared Symbicort Turbuhaler with standard COPD therapy to evaluate safety and efficacy. Results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Symbicort Turbuhaler (budesonide/formoterol)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease | Phase 3 | Status: COMPLETED | Results posted: 2013-12-05